Join us for this webinar, which will bring payer representatives from the UK (Andrew Walker), Germany (Frank-Ulrich Fricke), and Italy (Gianluigi Casadei) alongside an industry representative to discuss how payers will respond to this changing C> landscape and how manufacturers can proactively mitigate their strategies.
Why are some drugs that may be demonstrated as cost-effective not being recommended for reimbursement? PRECISIONadvisors Richard Macaulay and his co-author have published this influential study, uncovering that the NICE ICER thresholds have declined by 42.9% in real terms since 2004 (without accounting for inflation).
Congratulations to Richard Macaulay on his well-attended presentation “The New SMC-Ultra-Orphan Pathway: HTA Best Practice for Very Rare Diseases?” at Virtual ISPOR 2021. In case you missed this insightful presentation, it is now available on-demand.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
